newsfilter
← Latest News
Business Wire·

Durata Therapeutics Presenting Two Abstracts Concerning Dalbavancin at IDWeek 2012

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that data from two clinical trials of its lead product candidate, dalbavancin, will be presented in two posters during the IDWeek conference in San Diego from October 17-21, 2012.